Kingdon Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Kingdon Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-67,055	Closed	-$824K	–	134
2017 Q3	$824K	Sell	67,055 -539,355	-89%	-$7.96M	0.05%	107
2017 Q2	$9.97M	Sell	606,410 -1,083,863	-64%	-$16.8M	0.68%	50
2017 Q1	$24.2M	Buy	1,690,273 +472,698	+39%	+$7.01M	1.33%	24
2016 Q4	$16.8M	Buy	1,217,575 +407,909	+50%	+$6.54M	0.81%	43
2016 Q3	$14.6M	Buy	809,666 +315,286	+64%	+$5.07M	0.67%	37
2016 Q2	$7.09M	Sell	494,380 -30,000	-6%	-$407K	0.39%	66
2016 Q1	$6.27M	Sell	524,380 -250,000	-32%	-$2.62M	0.34%	67
2015 Q4	$10.3M	Buy	774,380 +249,380	+48%	+$3.07M	0.5%	58
2015 Q3	$5.64M	Buy	+525,000	New	+$5.73M	0.27%	78

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UIM

USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Kingdon Capital Management's LXRX Position: Q4 2017 in Review

Kingdon Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 67,055 shares — an estimated $824K sold.

Kingdon Capital Management first reported a position in LXRX in Q3 2015 and held it in 9 quarters. The position peaked at $24.2M in Q1 2017. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

Kingdon Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Kingdon Capital Management sold 67,055 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $824K.
Kingdon Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Kingdon Capital Management's Lexicon Pharmaceuticals position peaked at $24.2M in Q1 2017.
133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Kingdon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.